A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Triple Negative Breast Cancer
Interventions: BIOLOGICAL: N-803|BIOLOGICAL: PD-L1 t-haNK|DRUG: Sacituzumab Govitecan-Hziy|DRUG: Cyclophosphamide
Sponsor: ImmunityBio, Inc.